Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eun Young | - |
dc.contributor.author | Yechieli, Raphael | - |
dc.contributor.author | Kim, Jin Koo | - |
dc.contributor.author | Mikkelsen, Tom | - |
dc.contributor.author | Kalkanis, Steven N. | - |
dc.contributor.author | Rock, Jack | - |
dc.contributor.author | Rosenblum, Mark | - |
dc.contributor.author | Ryu, Samuel | - |
dc.date.available | 2020-02-28T18:44:14Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 0167-594X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12955 | - |
dc.description.abstract | Glioblastoma multiforme (GBM) invades beyond enhancing boundaries, and tumor cells are believed to exist in edematous peritumoral regions. We hypothesize that the concomitant treatment of both enhancing and FLAIR abnormalities on MRI by fractionated radiosurgery (FRS) would reduce local and regional recurrence. The purpose of this study was to demonstrate patterns of failure after FRS with simultaneous differential doses to two different target volumes of contrast enhancing lesions with/without FLAIR abnormality in recurrent GBM. Fifty-three patients with recurrent GBM were treated with FRS between 2008 and 2012. FRS was offered for the patients who had progressive tumors after the initial surgical resection followed by chemoradiation, and second-line chemotherapy. Radiosurgery Regimen A was 32 Gy (8 Gy x 4 treatments) to the contrast enhancing lesion only. Regimen B was 32 Gy (8 Gy x 4) to the contrast enhancing lesion and 24 Gy (6 Gy x 4) to the FLAIR abnormality delivered concomitantly. The study endpoint was radiographic failure on MRI at 2 months after FRS. Median survival after FRS was 7.5 months, and median progression-free survival after FRS was 4 months. Overall 82.4 % (42/51 lesions) recurred during follow-up. The local and regional failure rate was significantly lower in Regimen B (52 %) than in Regimen A (86.7 %) (p = 0.003). No sign of tumor progression in 10 % of Regimen A versus 28.6 % of Regimen B was shown during followup (p = 0.04). Instead, distant failure rate was higher in Regimen B. In conclusions, FRS was found to be a safe and effective salvage therapy for recurrent GBM. FRS to both contrast enhancing and FLAIR abnormalities appeared to improve local tumor control, and reduce regional tumor progression. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | JOURNAL OF NEURO-ONCOLOGY | - |
dc.subject | HIGH-GRADE GLIOMAS | - |
dc.subject | STEREOTACTIC RADIOSURGERY | - |
dc.subject | MALIGNANT GLIOMAS | - |
dc.subject | ADJUVANT TEMOZOLOMIDE | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | CONCOMITANT | - |
dc.subject | EFFICACY | - |
dc.subject | REIRRADIATION | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | SURVIVAL | - |
dc.title | Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000329622300011 | - |
dc.identifier.doi | 10.1007/s11060-013-1290-4 | - |
dc.identifier.bibliographicCitation | JOURNAL OF NEURO-ONCOLOGY, v.116, no.2, pp.291 - 297 | - |
dc.identifier.scopusid | 2-s2.0-84893691085 | - |
dc.citation.endPage | 297 | - |
dc.citation.startPage | 291 | - |
dc.citation.title | JOURNAL OF NEURO-ONCOLOGY | - |
dc.citation.volume | 116 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Kim, Eun Young | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Glioblastoma multiforme | - |
dc.subject.keywordAuthor | Radiosurgery | - |
dc.subject.keywordAuthor | Failure patterns | - |
dc.subject.keywordAuthor | Outcomes | - |
dc.subject.keywordPlus | HIGH-GRADE GLIOMAS | - |
dc.subject.keywordPlus | STEREOTACTIC RADIOSURGERY | - |
dc.subject.keywordPlus | MALIGNANT GLIOMAS | - |
dc.subject.keywordPlus | ADJUVANT TEMOZOLOMIDE | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | CONCOMITANT | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | REIRRADIATION | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.